According to @CNBC, Novo Nordisk shares fell about 10% after its Alzheimer’s drug trial failed to hit a key target, triggering an immediate downside reaction in the stock (source: CNBC). @CNBC also indicates the report did not cite any direct impact on cryptocurrency markets, leaving digital assets unaffected by this headline based on the information provided (source: CNBC).